SPDR Gold Trust vs Incyte Corporation — how do they compare? SPDR Gold Trust trades at $404.29, while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| GLD | INCY | |
|---|---|---|
52-Week High | $495.90 | $129.93 |
52-Week Low | $305.27 | $81.61 |
Market Cap | — | $24.54B |
Sector | — | Health |
Enterprise Value | — | $20.04B |
Signals from Pluang's Aura AI — not financial advice
GLD trades at $404.93, up 0.57% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent news highlights gold's strength amid cooling inflation and geopolitical tensions, with spot gold reaching multi-month highs. The ETF shows momentum but faces resistance near $405.
The outlook remains positive due to safe-haven demand and central bank buying, though high RSI suggests near-term consolidation risks. Upside potential exists toward $4,500, but investors should monitor inflation data and Fed policy for directional cues amid elevated volatility.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →